The biggest European round this month wears a lab coat
On 15 July 2026, Neko Health confirmed a 700 million dollar Series C, about 645 million euros or 545 million pounds, that values the company at close to 7 billion dollars, roughly 6.4 billion euros. That is about four times the 1.7 billion dollar mark set at its Series B in January 2025. Founded in Sweden by Spotify's Daniel Ek and Hjalmar Nilsonne, Neko runs full-body-scan clinics and sells a single scan for 299 pounds in the UK and 2,750 kronor in Sweden.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with Atomico, General Catalyst and Lakestar returning and Mark Zuckerberg and OpenAI among new backers. Neko says more than 100,000 people across the UK and Sweden have taken a scan, with a waitlist above 350,000. Notably, the cash funds a US launch, with a first Manhattan clinic planned for later this year, not more European expansion.
The product is the data, not the scan
Read this as a business, not a clinic. A single Neko visit is a 60-minute, non-invasive, radiation-free session that the company says captures millions of individual data points per person. Repeated over years across a growing membership, that is a longitudinal, consented health-data set at a scale very few organizations hold. The scan is the acquisition channel; the data platform is the asset.
That reframes the valuation. Investors are not paying 7 billion dollars for a chain of scanning rooms, which is capital-heavy and slow to replicate. They are paying for a proprietary data flywheel and the software layered on top, the same pattern that made Ek's first company valuable. Whether that thesis holds is the open question, but it is the thesis being funded.
Why an owner should read a health round as a tech round
Here is the owner-facing part. Preventive scanning is moving from a curiosity toward a benefit line, the way gym memberships and mental-health apps did before it. A 350,000-person waitlist and celebrity-heavy cap table are exactly how a category crosses from niche into something HR is asked to offer. Budget it, and it becomes a recurring per-employee cost with a data trail attached.
That trail is the catch. The moment a scan-as-a-benefit lands on your desk, you are not buying a wellness perk, you are routing sensitive employee data to a third party under a contract someone has to read. The question is not whether the scan is worth its sticker price; it is where the resulting data lives, who can query it, and what happens to it if the vendor is acquired.
A European champion aimed at America
There is a sovereignty note underneath the numbers. Neko is a European deep-tech company raising at 7 billion dollars and spending it to cross the Atlantic, with American strategic money, including OpenAI and Zuckerberg, buying into the story. That is the healthier version of the usual European narrative: a home-grown champion strong enough to export west rather than be absorbed.
It also shows where European capital still concentrates. This round is heavy with the same names that back the continent's biggest software bets, now pointed at physical-world data collection. For owners tracking where the next platform layer forms, health data gathered at scale is quietly becoming one of them, and Europe has a lead in this particular race worth watching.
The bottom line
Treat Neko's raise as a category signal, not a gadget story: preventive scanning just got priced as a platform, and the day it reaches your benefits menu the real decision is about data, not health. Before you sign, ask where the records are held, who else can read them, and what survives an acquisition; the sticker price is the easy part, and the part that will not come back to bite you.
Read next: Stripe Bid $53 Billion for Its Biggest Rival | Moneybox Became a Unicorn Without Raising a Penny
